175 related articles for article (PubMed ID: 31785830)
1. Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial.
Fernando IN; Bowden SJ; Herring K; Brookes CL; Ahmed I; Marshall A; Grieve R; Churn M; Spooner D; Latief TN; Agrawal RK; Brunt AM; Stevens A; Goodman A; Canney P; Bishop J; Ritchie D; Dunn J; Poole CJ; Rea DW;
Radiother Oncol; 2020 Jan; 142():52-61. PubMed ID: 31785830
[TBL] [Abstract][Full Text] [Related]
2. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Cameron D; Morden JP; Canney P; Velikova G; Coleman R; Bartlett J; Agrawal R; Banerji J; Bertelli G; Bloomfield D; Brunt AM; Earl H; Ellis P; Gaunt C; Gillman A; Hearfield N; Laing R; Murray N; Couper N; Stein RC; Verrill M; Wardley A; Barrett-Lee P; Bliss JM;
Lancet Oncol; 2017 Jul; 18(7):929-945. PubMed ID: 28600210
[TBL] [Abstract][Full Text] [Related]
3. Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity.
Fernando IN; Lax S; Bowden SJ; Ahmed I; Steven JH; Churn M; Brunt AM; Agrawal RK; Canney P; Stevens A; Rea DW
Clin Oncol (R Coll Radiol); 2023 Jun; 35(6):397-407. PubMed ID: 37012180
[TBL] [Abstract][Full Text] [Related]
4. Concurrent chemoradiotherapy in adjuvant treatment of breast cancer.
Ismaili N; Mellas N; Masbah O; Elmajjaoui S; Arifi S; Bekkouch I; Ahid S; Bazid Z; Tazi MA; Erraki A; El Mesbahi O; Benjaafar N; El Gueddari Bel K; Ismaili M; Afqir S; Errihani H
Radiat Oncol; 2009 Apr; 4():12. PubMed ID: 19351405
[TBL] [Abstract][Full Text] [Related]
5. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
Brunt AM; Haviland JS; Wheatley DA; Sydenham MA; Bloomfield DJ; Chan C; Cleator S; Coles CE; Donovan E; Fleming H; Glynn D; Goodman A; Griffin S; Hopwood P; Kirby AM; Kirwan CC; Nabi Z; Patel J; Sawyer E; Somaiah N; Syndikus I; Venables K; Yarnold JR; Bliss JM;
Health Technol Assess; 2023 Nov; 27(25):1-176. PubMed ID: 37991196
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; D'Amico R; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Gribaudo S; Provencher D; Hanzen C; Kruitwagen RF; Smit VTHBM; Singh N; Do V; Lissoni A; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2019 Sep; 20(9):1273-1285. PubMed ID: 31345626
[TBL] [Abstract][Full Text] [Related]
7. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
Velikova G; Morden JP; Haviland JS; Emery C; Barrett-Lee P; Earl H; Bloomfield D; Brunt AM; Canney P; Coleman R; Verrill M; Wardley A; Bertelli G; Ellis P; Stein R; Bliss JM; Cameron D;
Lancet Oncol; 2023 Dec; 24(12):1359-1374. PubMed ID: 37926100
[TBL] [Abstract][Full Text] [Related]
8. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.
Perrone F; Nuzzo F; Di Rella F; Gravina A; Iodice G; Labonia V; Landi G; Pacilio C; Rossi E; De Laurentiis M; D'Aiuto M; Botti G; Forestieri V; Lauria R; De Placido S; Tinessa V; Daniele B; Gori S; Colantuoni G; Barni S; Riccardi F; De Maio E; Montanino A; Morabito A; Daniele G; Di Maio M; Piccirillo MC; Signoriello S; Gallo C; de Matteis A
Ann Oncol; 2015 Apr; 26(4):675-682. PubMed ID: 25488686
[TBL] [Abstract][Full Text] [Related]
9. Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial.
Tobias JS; Monson K; Gupta N; Macdougall H; Glaholm J; Hutchison I; Kadalayil L; Hackshaw A;
Lancet Oncol; 2010 Jan; 11(1):66-74. PubMed ID: 19875337
[TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
11. Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer.
Kim K; Chie EK; Han W; Noh DY; Oh DY; Im SA; Kim TY; Bang YJ; Ha SW
Tumori; 2011; 97(3):280-5. PubMed ID: 21789003
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
16. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
[TBL] [Abstract][Full Text] [Related]
17. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Haddad R; O'Neill A; Rabinowits G; Tishler R; Khuri F; Adkins D; Clark J; Sarlis N; Lorch J; Beitler JJ; Limaye S; Riley S; Posner M
Lancet Oncol; 2013 Mar; 14(3):257-64. PubMed ID: 23414589
[TBL] [Abstract][Full Text] [Related]
20. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
